Vincenzo Atella1, Joanna Aleksandra Kopinska. 1. Department of Economics and Finance, University of Rome Tor Vergata, CHP PCOR Stanford University, Via Columbia, 2, 00133, Rome, Italy, atella@uniroma2.it.
Abstract
OBJECTIVES: In this article we investigate the causal effect of cost-sharing schemes on compliance with statins in a quantile regression framework. METHODS: We use the health search CSD-LPD data, a longitudinal observational dataset containing computer-based patient records collected by Italian general practitioners. We exploit a series of natural experiments referring to several introductions of co-payment schemes in some of the Italian regions between 2000 and 2009. We adopt an extended difference-in-differences approach to provide quantile estimates of the impact of co-payments on compliance. RESULTS: We find that (i) introduction of co-payments hurts residents of regions with worse quality and provision of health care; (ii) within these regions, co-payments were particularly harmful for high compliers; (iii) gender, clinical history and geographic residence are important determinants of compliance among poor compliers; (iv) compliance decreases with the potency and dosage of statins, particularly for poor compliers. CONCLUSIONS: In the presence of inefficient health-care provision, co-payments are harmful for drug compliance, and this is especially true for patients who are originally good compliers.
OBJECTIVES: In this article we investigate the causal effect of cost-sharing schemes on compliance with statins in a quantile regression framework. METHODS: We use the health search CSD-LPD data, a longitudinal observational dataset containing computer-based patient records collected by Italian general practitioners. We exploit a series of natural experiments referring to several introductions of co-payment schemes in some of the Italian regions between 2000 and 2009. We adopt an extended difference-in-differences approach to provide quantile estimates of the impact of co-payments on compliance. RESULTS: We find that (i) introduction of co-payments hurts residents of regions with worse quality and provision of health care; (ii) within these regions, co-payments were particularly harmful for high compliers; (iii) gender, clinical history and geographic residence are important determinants of compliance among poor compliers; (iv) compliance decreases with the potency and dosage of statins, particularly for poor compliers. CONCLUSIONS: In the presence of inefficient health-care provision, co-payments are harmful for drug compliance, and this is especially true for patients who are originally good compliers.
Authors: Jeffrey J Ellis; Steven R Erickson; James G Stevenson; Steven J Bernstein; Renee A Stiles; A Mark Fendrick Journal: J Gen Intern Med Date: 2004-06 Impact factor: 5.128
Authors: Mulugeta Gebregziabher; Cheryl P Lynch; Martina Mueller; Gregory E Gilbert; Carrae Echols; Yumin Zhao; Leonard E Egede Journal: BMC Med Res Methodol Date: 2011-06-06 Impact factor: 4.615